"Personalized medicine is based on the application of genomic and molecular data to better target the delivery of health care to the right person at the right time using the most effective and safe treatment available."
Erwin P. Böttinger, MD
Director of the Charles Bronfman Institute for Personalized Medicine
Irene and Dr. Arthur Fishberg Chair and Professor in Medicine
Professor of Pharmacology and Systems Therapeutics
About 10 years ago, I began to realize that the prospect of comprehensive analysis and interpretation of human genomes and wide-spread use of electronic health records would one day become practical and affordable. I rededicated my successful career as physician-scientist to the new vision of personalized data-driven healthcare. For me, the first step towards this was joining Mount Sinai in 2004, because here I find exceptional support and commitment to pioneer in genomics and personalized data-driven healthcare at every level.
Realizing that Mount Sinai was the right institution, I began in 2005 to assemble a multi-disciplinary team of expert colleagues to develop the ambitious and visionary blueprint for what should become The Charles Bronfman Institute for Personalized Medicine in 2007. We created the BioMe Biobank Platform with the goal of enrolling Mount Sinai patients into a clinical care cohort that links genetic and biomarker data with clinical data in the patient’s electronic health record. In November 2012, enrollment surpassed 23,000 patients from the diverse communities served by Mount Sinai. I am proud that through their participation in the BioMe Biobank Program, our Mount Sinai patients are providing important de-identified clinical and genetic data to numerous local, national and global research projects that seek to improve health outcomes.
Encouraged by the overwhelmingly positive response and enthusiasm of our patients and communities for personalized genomic medicine, we created another innovative platform that links with Mount Sinai’s electronic health record system and allows us to deliver custom-tailored, personalized clinical decision guidelines incorporating a patient’s unique clinical and genetic data in their clinical care in ‘real-time at the point-of-care,' that means while our patients see their doctor. Through our CLIPMERGE Program, standing for Clinical Implementation of Personalized Medicine through Electronic Health Records and Genomics, Mount Sinai patients participating in BioMe may already benefit from anticoagulant and lipid lowering treatments that are custom-tailored for safety and efficacy based on their own DNA.
Our success has not gone unnoticed. World-class researchers join Mount Sinai and our Institute attracted by the outstanding translational research environment of the institution and by IPM’s innovative BioMe and CLIPMERGE platforms. Our faculty are engaged in groundbreaking research that will lead to a better understanding of many common diseases, including obesity, diabetes, high blood pressure, heart disease, kidney disease, hepatitis, asthma and arthritis.
This is an exciting time of fundamental transformation, through data-driven personalized medicine. At Mount Sinai, personalized healthcare is now a reality. I am privileged to have the opportunity to contribute to leading innovations within personalized healthcare. I am grateful to my colleagues, staff; but most of all, I am grateful to our participating patients. Without the support and commitment of our patients, none of this would be possible.
With Best Regards,
Erwin P. Böttinger, MD